Defense Advanced Research Projects AgencyTagged Content List

Infectious Disease

Relating to ailments caused by pathogens

Showing 55 results for Disease RSS
Viral pathogens pose a continuous and shifting biological threat to military readiness and national security overall in the form of infectious disease with pandemic potential. Today’s limited vaccines and other antivirals are often circumvented by quickly mutating viruses that evolve to develop resistance to treatments that are carefully formulated to act only specific strains of a virus.
The Microphysiological Systems (MPS) program supports military readiness by enabling timely evaluation of the safety and efficacy of novel medical countermeasures against a wide range of natural and man-made health threats, including emerging infectious disease and chemical or biological attack. Testing these types of countermeasures is particularly challenging using current methods because it is often both unethical and impractical to evaluate countermeasures using human clinical trials. Instead, the U.S. Food and Drug Administration (FDA) must base its determination of efficacy and toxicity on data from animal studies, despite the fact that animal models have limited relevance to humans and poorly predict effects in humans.
07/10/2015
The White House announced the BRAIN initiative in April 2013. Today, the initiative is supported by several federal agencies as well as dozens of technology firms, academic institutions, scientists and other key contributors to the field of neuroscience. DARPA is supporting the BRAIN initiative through a number of programs, continuing a legacy of DARPA investment in neurotechnology that extends back to the 1970s.
The Pandemic Prevention Platform (P3) program aims to support military readiness and global stability through pursuit of novel methods to dramatically accelerate discovery, integration, pre-clinical testing, and manufacturing of medical countermeasures against infectious diseases. P3 confronts the reality that Department of Defense (DoD) personnel are not only deployed around the world for routine operations, but are often among the first responders to outbreaks of emerging or re-emerging disease with pandemic potential (e.g., Ebola). P3 aims specifically to develop a scalable, adaptable, rapid response platform capable of producing relevant numbers of doses against any known or previously unknown infectious threat within 60 days of identification of such a threat in order to keep the outbreak from escalating and decrease disruptions to the military and homeland.
The Pathogen Predators program focuses on force readiness and homeland protection through development of novel countermeasures against biological threats involving bacterial agents. Currently, the most common defense against such a threat is traditional antibiotics, but while such antibiotics have been remarkably effective in the past, their widespread use has heightened the risk of our troops contracting antibiotic-resistant bacterial infections that are difficult or impossible to treat. A new type of countermeasure is needed to overcome the threat posed by antibiotic-resistant bacteria.